Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background Ketamine has proven to have rapid, robust antidepressant effects on treatment-resistant depression. However, whether repeated ketamine infusions would cause short-and long-term neurocognitive impairments was not clear. Our aims were to investigate the neurocognitive effects of six ketamine infusions and to examine the association between these infusions and the antidepressant response in patients with unipolar and bipolar depression. Methods Six intravenous infusions of ketamine (0.5 mg/kg) over a 12-day period were administered to 84 patients with unipolar and bipolar depression. Severity of depressive symptoms and four domains of neurocognition, including speed of processing, working memory, visual learning and verbal learning, were assessed at baseline, one day following the last infusion and again two weeks post-infusion. Results Significant improvements were found on speed of processing ( F=9.344, p Conclusions Our findings suggest that neurocognitive function would not deteriorate after six ketamine infusions, while verbal learning and speed of processing improved over 13 days and 26 days of observation, respectively. However, this change was mainly accounted for by improvements in severity of depressive symptoms over time. Greater baseline visual learning predicted an antidepressant response over six ketamine infusions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Processing speed and verbal learning improved, but this was significantly correlated with improvement in depressive symptoms.166,167”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [166]
In the citing paper
“Three groups of patients – with treatment-resistant unipolar and bipolar depression,166 TRD167 and anxious/non-anxious depression168 – were given six ketamine infusions over 12 days, with similar cognitive testing in a 2 week follow-up period. No deterioration in cognitive function was seen in any of the studies.”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [166]
In the citing paper
“In terms of predictive cognitive variables of response to ketamine, greater baseline visual learning predicted degree of MDD response to ketamine treatment in two of the above studies.166,168”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [166]
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258
RetractedAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 3×
“In healthy individuals, an acute dose of ketamine induced marked cognitive impairments (Carter et al., 2013; Krystal et al., 1994).”
BackgroundResultThe MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 6×
“One explanation for this result is that larger hippocampal volumes and high BDNF levels are indicators of patients who had a higher intrinsic “restorative” capacity of neuronal plasticity to synergize with the actions of antidepressants to alleviate depression (Colle et al., 2016; Sen et al., 2008; Wolkowitz et al., 2…”
BackgroundInfluentialSen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 6×
“A single subanesthetic (0.5 mg/kg) dose infusion of intravenous ketamine has rapid-acting and robust antidepressant effects, but the effect is relatively short-lived, usually ranging from 3–7 days post-infusion(Berman et al., 2000; Murrough et al., 2013a).”
BackgroundMethodInfluentialDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 3×
“…decades, ketamine has demonstrated rapid-onset antidepressant effects in patients with treatment-resistant depression (TRD) (Berman et al., 2000; Diazgranados et al., 2010a; Murrough et al., 2013a; Zarate et al., 2006) and rapid reductions in suicidal cognition in patients with suicidal…”
BackgroundMethodInfluentialMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 6×
“A single subanesthetic (0.5 mg/kg) dose infusion of intravenous ketamine has rapid-acting and robust antidepressant effects, but the effect is relatively short-lived, usually ranging from 3–7 days post-infusion(Berman et al., 2000; Murrough et al., 2013a).”
BackgroundMethodInfluential
Research works printed but not linked: 1
- Colle R, 2016, World J Biol Psychiatry, 1
Cited by
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Marcantoni, W. S., Akoumba, B. S., Wassef, M., Mayrand, J., Lai, H., Richard-Devantoy, S., & Beauchamp, S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.007 · Cited by 246
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Cognitive Impairment in Patients with Bipolar Disorder: Impact of Pharmacological Treatment
Xu, N., Huggon, B., & Saunders, K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00688-2 · Cited by 98
Zhan, Y., Zhou, Y., Zheng, W., Liu, W., Wang, C., Lan, X., Deng, X., Xu, Y., Zhang, B., & Ning, Y. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00933-z · Cited by 81
Self-citation
Metadata
- Authors
- Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhan, Y., Li, H., Chen, L., Li, M., & Ning, Y.
- Affiliations
- Guangzhou Medical University (CN)
- State Key Laboratory of Diagnosis and Treatment of Infectious Diseases (CN)
- Corresponding author
- Ning, Yuping
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-09-27
- Volume
- 32
- Issue
- 10
- Pages
- 1118-1126
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2893295941
- Cited by
- 73
- References
- 38
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 10 · 2022: 12 · 2021: 12 · 2020: 14 · 2019: 3 · 2018: 1
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2016YFC0906300)
- Science and Technology Department of Guangdong Province major science and technology (2016B010108003)
- Planed Science and Technology Projects of Guangzhou (201607010131)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- ketamine, neurocognitive effects, antidepressant response, major depressive disorder, bipolar depression, processing speed, verbal learning, visual learning, working memory, depressive symptoms, treatment-resistant depression
- MeSH terms
- Adult, Antidepressive Agents, Bipolar Disorder, Cognition, Major Depressive Disorder, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Ketamine, Male, Memory, Short-Term, Middle Aged, Neuropsychological Tests, Severity of Illness Index, Time Factors, Verbal Learning, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. https://app.cochat.ai/papers/10.1177/0269881118798614
- The paper
- Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhan, Y., Li, H., Chen, L., Li, M., & Ning, Y. (2018). Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. Journal of Psychopharmacology. https://doi.org/10.1177/0269881118798614
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.